ArticleCancer informatics2026
Trends and Disparities in Mortality from Malignant Parotid Gland Tumors in the United States, 1999-2023: A Population-Based Analysis.
Article in Cancer informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Malignant parotid gland tumors account for less than 1% of all cancers yet represent a substantial proportion of head and neck malignancies. Long-term mortality trends and demographic disparities remain poorly defined. This study examined mortality trends and disparities across demographic and geographic subgroups in the United States. Methods: This repeated cross-sectional study analyzed CDC WONDER death certificate data for malignant parotid gland tumors (ICD-10-CM C07) from 1999 to 2023. AAMRs were calculated using the 2000 US standard population. Joinpoint regression estimated APCs and AAPCs with 95% CIs. Mortality was stratified by age, sex, race/ethnicity, and geography. Results: During the study period, 15,133 deaths from malignant parotid gland tumors were recorded. Annual deaths increased from 491 in 1999 to 696 in 2023, but the overall AAMR remained stable (AAPC = -0.09, 95% CI, -0.43 to 0.25). Declines were observed among females, males, adults aged 45 to 74 years, the Northeast region, Florida, and New York. Mortality increased among adults aged 85 years or older (AAPC = 1.22, 95% CI, 0.67 to 1.77). Trends for NH White and NH Black populations were stable; smaller race/ethnicity groups had limited or unstable estimates. Conclusion: Overall mortality from malignant parotid gland tumors remained stable from 1999 to 2023. This stable national pattern masked declines in selected strata and increasing mortality among adults aged 85 years or older. Because CDC WONDER lacks clinical, treatment, socioeconomic, and tumor-specific variables, these findings should be interpreted as descriptive mortality patterns rather than causal evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.